DXCM Dexcom Inc

Price (delayed)

$131.36

Market cap

$52.24B

P/E Ratio

79.61

Dividend/share

N/A

EPS

$1.65

Enterprise value

$53.92B

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California. Dexcom was founded in ...

Highlights
Dexcom's net income has soared by 119% YoY and by 18% from the previous quarter
The EPS has soared by 117% YoY and by 18% QoQ
The debt has increased by 22% YoY
The gross margin has declined by 2.5% year-on-year

Key stats

What are the main financial stats of DXCM
Market
Shares outstanding
397.68M
Market cap
$52.24B
Enterprise value
$53.92B
Valuations
Price to book (P/B)
22.54
Price to sales (P/S)
13.48
EV/EBIT
67.9
EV/EBITDA
54.41
EV/Sales
14.18
Earnings
Revenue
$3.8B
EBIT
$794.1M
EBITDA
$991M
Free cash flow
$583.5M
Per share
EPS
$1.65
Free cash flow per share
$1.5
Book value per share
$5.83
Revenue per share
$9.74
TBVPS
$16.24
Balance sheet
Total assets
$6.48B
Total liabilities
$4.24B
Debt
$2.53B
Equity
$2.25B
Working capital
$3.03B
Liquidity
Debt to equity
1.13
Current ratio
2.9
Quick ratio
2.43
Net debt/EBITDA
1.7
Margins
EBITDA margin
26.1%
Gross margin
62.8%
Net margin
16.8%
Operating margin
17.1%
Efficiency
Return on assets
9.8%
Return on equity
29.4%
Return on invested capital
12%
Return on capital employed
16.2%
Return on sales
20.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DXCM stock price

How has the Dexcom stock price performed over time
Intraday
-0.42%
1 week
3.39%
1 month
-1.87%
1 year
10.77%
YTD
5.86%
QTD
-5.29%

Financial performance

How have Dexcom's revenue and profit performed over time
Revenue
$3.8B
Gross profit
$2.39B
Operating income
$651.6M
Net income
$639.3M
Gross margin
62.8%
Net margin
16.8%
Dexcom's net income has soared by 119% YoY and by 18% from the previous quarter
The net margin has soared by 73% YoY and by 13% from the previous quarter
DXCM's operating income has surged by 64% year-on-year and by 9% since the previous quarter
The operating margin has increased by 31% year-on-year and by 3.6% since the previous quarter

Growth

What is Dexcom's growth rate over time

Valuation

What is Dexcom stock price valuation
P/E
79.61
P/B
22.54
P/S
13.48
EV/EBIT
67.9
EV/EBITDA
54.41
EV/Sales
14.18
The EPS has soared by 117% YoY and by 18% QoQ
The stock's price to earnings (P/E) is 39% less than its 5-year quarterly average of 130.3 and 22% less than its last 4 quarters average of 101.5
The company's equity rose by 9% QoQ
DXCM's P/B is 4.8% above its 5-year quarterly average of 21.5 and 3.9% above its last 4 quarters average of 21.7
Dexcom's revenue has increased by 26% YoY and by 5% from the previous quarter
The stock's price to sales (P/S) is 15% less than its 5-year quarterly average of 15.9

Efficiency

How efficient is Dexcom business performance
The ROE has soared by 112% year-on-year and by 18% since the previous quarter
Dexcom's ROA has soared by 75% YoY and by 14% from the previous quarter
The ROS rose by 46% YoY and by 3.5% QoQ
DXCM's return on invested capital is up by 43% year-on-year and by 2.6% since the previous quarter

Dividends

What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DXCM.

Financial health

How did Dexcom financials performed over time
The company's total assets is 53% higher than its total liabilities
Dexcom's current ratio has increased by 44% YoY and by 2.1% QoQ
The quick ratio has grown by 41% year-on-year and by 2.1% since the previous quarter
The debt is 13% more than the equity
DXCM's debt to equity is up by 22% YoY but it is down by 8% QoQ
The debt has increased by 22% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.